BPH’s Investee Cortical Confirms Filing of New International Patent Application

  • Jul 03, 2020 AEST
  • Team Kalkine
BPH’s Investee Cortical Confirms Filing of New International Patent Application

Summary

  • BPH’s investee Cortical has confirmed the filing of a new international patent application.
  • The arising IP will be protected as appropriate throughout the commercialisation process to retain Cortical’s potent competitive position.
  • Cortical’s BARM is set to be presented at the 2020 Spring Development seminar and Council of the Korean Association of Anaesthesia in July.

In a significant development, BPH Energy Limited (ASX:BPH) investee Cortical Dynamics Ltd has confirmed the filing of a new international patent application, carrying Application No. PCT/AU2020/050535. Cortical informed that the patent application has been lodged for “Apparatus and process for measuring brain activity”.

Medical device technology player, Cortical has developed a next-gen Brain Anaesthesia Response Monitor (BARM) to better monitor the effect of anaesthetic agents on patient’s brain activity, supporting anaesthetists to keep patients anaesthetised in an optimal way.

Source: Cortical's report

Cortical has created a comprehensive patent portfolio covering brain function monitor BARM, that provides it with a crucial patent protection across several significant brain monitoring markets.

Cortical’s Robust Patent Position

Cortical’s competitive advantage across other brain monitoring markets is underpinned by its robust patent position, encompassed by five patent families and twenty-two granted patents. All these five patent families have advanced along PCT (Patent Co-operation Treaty) path, with patents progressing into national patent applications.

Cortical’s patents cover BARM’s uniquely defined measures - Cortical Input (CI) and Composite Cortical State (CCS), that have been recognised by the world’s leading experts in anaesthesia. While CCS measures the consciousness level of the patient under anaesthetic, CI measures analgesia or pain input received by the brain.

Currently, Cortical has patents awarded in Japan, the People’s Republic of China, Australia, New Zealand, the United States and Europe.

The strength of Cortical’s patents has been demonstrated several times in the past when the Company’s prior patents work were cited by various countries’ patent offices in Cortical’s later patent sequence.

As per Cortical, the arising Intellectual property (IP) will be protected as appropriate throughout the commercialisation process to retain Cortical’s potent competitive position.

BARM to be Exhibited in Korea

Cortical’s BARM is set to be presented at the 2020 Spring Development seminar and Council of the Korean Association of Anaesthesia. The Korean Anaesthetic Conference is scheduled to be held at the BEXCO Convention Hall in Busan South Korea on 24th and 25th July 2020.

Cortical lately notified that its Korean distributor, Globaluck will exhibit BARM at the conference. Both Globaluck and Cortical are presently in the concluding phase of the Korean regulatory approval process for BARM with the Korean Ministry of Food and Drug Safety.

To recall, Globaluck attained a certificate of approval for BARM from the KGMP (Korea Good Manufacturing Practice) in September last year.

Marking a quantum leap forward towards the advancement of BARM system, Cortical also signed Licence and Co-operation Agreement with health technology company Philips in June 2020.

BARM’s Competitive Advantage

According to Cortical, its BARM system is fundamentally different from its competitive technologies in various ways, including:

  • It exhibits sensitivity to a broad range of anaesthetic and sedative agents, comprising propofol, ketamine, sevoflurane, midazolam and nitrous oxide, some of which other depth of anaesthesia monitors fail to detect.
  • It detects the effects of both analgesic and hypnotic agents that no other depth of anaesthesia monitors can.
  • It produces a reading in just within two seconds in comparison to 30 seconds for the leading competitor, which is a major factor in optimising anaesthesia level.
  • It demonstrates a fall in awareness or sedation in completely paralysed patients.
  • It provides an accurate, non-invasive and reliable means to gauge the brain state consciousness and analgesia of an anaesthetised patient during surgery, which has the potential to offer several benefits.

Notably, exceptional features associated with BARM system provide a significant competitive advantage to BPH’s investee Cortical in the brain monitoring market. The latest filing of an international patent application is further likely to strengthen Cortical’s position, potentially delivering a substantial value in future.

BPH traded at $0.021 on 3 July 2020 (As at 3:44 PM AEST).

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK